Maryam Chenaghlou

Maryam Chenaghlou

Auto-generated profile, based on publicly available information

Maryam Chenaghlou

Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
NNNasim Naderi
Nasim Naderi
MCMaryam Chenaghlou
Maryam Chenaghlou
MMMarzieh Mirtajaddini
Marzieh Mirtajaddini
ZNZeinab Norouzi
Zeinab Norouzi
NMNasibeh Mohammadi
Nasibeh Mohammadi
RGReza Golpira
Reza Golpira
Introduction: Heart failure(HF) related hospitalization constitutes a significant proportion of healthcare cost. Unchanging rates of readmission during recent years, shows the importance of addressing this problem. Methods: Patients admitted with heart failure diagnosis in our institution during April 2018to August 2018 were selected. Clinical, para-clinical and imaging data were recorded. All included patients were followed up for 6 months. The primary endpoints of the study were prevalence of early readmission and the predictors of that. Secondary end points were in-hospital and 6-month post-discharge mortality rate and late readmission rate. Results: After excluding 94 patients due to missing data, 428 patients were selected. Mean age of patients was 58.5 years (±17.4) and 61% of patients were male. During follow-up, 99patients (24%) were readmitted. Early re-admission (30-day) occurred in 27 of the patients(6.6%). The predictors of readmission were older age ( P=0.006), lower LVEF (P <0.0001), higher body weight (P=0.01), ICD/CRT implantation ( P=0.001), Lower sodium ( P=0.01), higher Pro-BNP(P=0.01), Higher WBC count (P=0.01) and higher BUN level (P=0.02). Independent predictors of early readmission were history of device implantation (P=0.007), lower LVEF (P=0.016), QRS duration more than 120 ms (P=0.037), higher levels of BUN (P=0.008), higher levels of Pro-BNP(P=0.037) and higher levels of uric acid (P=0.035). Secondary end points including in-hospital and 6-month post-discharge mortality occurred in 11% and 14.4% of patients respectively. Conclusion: Lower age of our heart failure patients and high prevalence of ischemic cardiomyopathy, necessitate focusing on more preventable factors related to heart failure.

1 December 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
ZMZahra Mahmoudi
Zahra Mahmoudi
MCMaryam Chenaghlou
Maryam Chenaghlou
Hossein ZareHossein Zare
Hossein Zare
NSNaser Safaei
Naser Safaei
MYMahmood Yousefi
Mahmood Yousefi
Introduction: Heart failure (HF) imposes a heavy economic burden on patients, their families, and society as a whole. Therefore, it is crucial to quantify the impact and dimensions of the disease in order to prioritize and allocate resources effectively.Methods: This study utilized a prevalence-based, bottom-up, and incidence-based Markov model to assess the cost of illness. A total of 502 HF patients (classes I–IV) were recruited from Madani Hospital in Tabriz between May and October 2022. Patients were followed up every two months for a minimum of two and a maximum of six months using a person-month measurement approach. The perspective of the study was societal, and both direct and indirect costs were estimated. Indirect costs were calculated using the Human Capital (HC) method. A two-part regression model, consisting of the Generalized Linear Model (GLM) and Probit model, was used to analyze the relationship between HF costs and clinical and demographic variables.Results: The total cost per patient in one year was 261,409,854.9 Tomans (21,967.21 PPP). Of this amount, 207,147,805.8 Tomans (17,407.38 PPP) (79%) were indirect costs, while 54,262,049.09 Tomans (4,559.84 PPP) (21%) were direct costs. The mean lifetime cost was 2,173,961,178 Tomans. Premature death accounted for the highest share of lifetime costs (48%), while class III HF had the lowest share (2%). Gender, having basic insurance, and disease class significantly influenced the costs of HF, while comorbidity and age did not have a significant impact. The predicted amount closely matched the observed amount, indicating good predictive power.Conclusion: This study revealed that HF places a significant economic burden on patients in terms of both direct and indirect costs. The substantial contribution of indirect costs, which reflect the impact of the disease on other sectors of the economy, highlights the importance of unpaid work. Given the significant variation in HF costs among assessed variables, social and financial support systems should consider these variations to provide efficient and fair support to HF patients.

3 January 2024 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MCMaryam Chenaghlou
Maryam Chenaghlou
FMFatemeh Abedi Mahzoon
Fatemeh Abedi Mahzoon
SHSina Hamzehzadeh
Sina Hamzehzadeh
ANAli Norouzi
Ali Norouzi
HSHadi Sahrai
Hadi Sahrai
EBErfan Banisefid
Erfan Banisefid
Background: Recent studies have shown that increases in serum UA levels are associated with adverse clinical outcomes in patients with chronic heart failure (CHF); the aim of this study was to determine the relationship between serum uric acid and total diuretic dose received during hospitalization in hospitalized patients with acute exacerbation of heart failure. The main purpose of this study is to determine the role of uric acid as a biomarker that can be a substitute for pro-BNP in clinical evaluation and the need for diuretics in hospitalized patients with acute heart failure. Methods: After approving the plan in the Research Council of the Heart Department and obtaining an ethical code from the Regional Committee on Research Ethics (Human Subjects Studies), the researcher referred to the archives of our center, the case of 100 patients diagnosed with acute heart failure. Cardiac patients were selected, and the information required for the study was collected using a pre-prepared data collection form, and the information was entered into SPSS software after categorization and appropriate analysis and statistical tests were performed on it. Were performed and in all statistical tests the statistical significance level was considered 0.05: Results: 100 patients with acute heart failure were included in this study with a mean age of 63.43 ± 14.78 years. 66% of them were men. The mean dose of furosemide in these patients was 680.92 ± 377.47 mg and the mean serum uric acid level in these patients was 8.55 ± 2.50 mg / dL. In the study of the relationship between the variables, there was a significant relationship between the dose of furosemide received with the serum level of serum uric acid (P = 0.017, r = 0.248 and P = 0.009, r = -0.267, respectively). There is also a significant relationship between serum uric acid level and patient mortality (P = 0.013, r = 0.247). However this relationship lost its significance after multivariate analysis. Conclusion: There is a significant relationship between serum uric acid level and diuretic use. However, in-hospital mortality is not related to uric acid levels at admission.

9 May 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MTMehrnoush Toufan
Mehrnoush Toufan
DADina Ashouri
Dina Ashouri
SHSina Hamzehzadeh
Sina Hamzehzadeh
BJBehnam Atashi Jahromi
Behnam Atashi Jahromi
MCMaryam Chenaghlou
Maryam Chenaghlou
Echocardiography is the standard tool for the evaluation of mitral regurgitation (MR). Although Two-dimensional echocardiography is the most recommended tool, it has some limitations. Three-dimensional echocardiography (3DE) is suggested to overcome these limitations, however, it is more time-consuming. Introducing a simplified and accurate 3-D method could be helpful in this regard. Patients diagnosed with significant MR who were referred to Shahid Madani heart center, Tabriz, Iran for evaluation of MR severity were entered in this study. Patients with prior MR surgery, poor image quality, and without self-consent for participation in the study were excluded. Two-dimensional transthoracic echocardiography (TTE) and 3D transesophageal echocardiography (TEE) were performed in all patients. MR severity was compared between these two methods and between direct planimetry (DP) of the vena contracta area (VCA) and 3D directed multiplanar reconstruction (MPR). A total of 53 patients were studied. Thirty-six (69.7%) of the patients were female. The mean age of patients was 66.21 ± 11.91 years. 3DVCA using DP was significantly correlated with the 2D method in terms of MR severity (p = 0.006). There was a significant correlation between the results of 3DE DP and 2DE magnetic resonance voiding cystography (MRVC) diameter (r = 0.503 and p = 0.0001). A significant correlation was also found between the result of DP and MPR-derived VCA using 3D (r = 0.97 and p = 0.0001). TEE is an invaluable method to decide the severity and mechanism of patients with MR, especially if TTE does not give adequate information. The method proposed in this study for evaluation of MR severity and mechanism using 3D TEE could be a helpful option, especially in the above-mentioned conditions. In this study, 3D direct planimetry had an acceptable correlation with 2DE MRVC and also with 3D MPR-derived VCA.

1 January 2021
Verified
Closed access
AAA. Amin
A. Amin
MCM. Chenaghlou
M. Chenaghlou
EZE. Zare
E. Zare
NNN. Naderi
N. Naderi
STS. Taghavi
S. Taghavi

28 November 2020 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
STSepideh Taghavi
Sepideh Taghavi
MCMaryam Chenaghlou
Maryam Chenaghlou
MMMarzieh Mirtajaddini
Marzieh Mirtajaddini
AAAhmad Amin
Ahmad Amin
NNNasim Naderi
Nasim Naderi
Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support for increasing survival. Considering the low availability and serious complications of these strategies,effective medical therapies for this group of patients would be pivotal for decreasing mortality and morbidity of them. Angiotensin receptor neprilysin inhibitor (ARNI) is a class of drugs approved for ambulatory heart failure patients. ARNI use like other groups of heart failure drugs has not been fully evaluated in end-stage heart failure patients. Herein, we describe four inotrope-dependent heart failure patients. Initiation of ARNI in these patients, lead to discontinuation of inotrope and reducing the need for inotrope in the follow-up period.